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Available online xxxxObjectives: The IFCC Committee on Reference Intervals and Decision Limits coordinated a global multicenter
study on reference values (RVs) to explore rational and harmonizable procedures for derivation of reference in-
tervals (RIs) and investigate the feasibility of sharing RIs through evaluation of sources of variation of RVs on a
global scale.
Methods: For the common protocol, rather lenient criteria for reference individualswere adopted to facilitate har-
monized recruitment with planned use of the latent abnormal values exclusion (LAVE) method. As of July 2015,
12 countries had completed their study with total recruitment of 13,386 healthy adults. 25 analytes were mea-
sured chemically and 25 immunologically. A serum panel with assigned valueswasmeasured by all laboratories.
RIs were derived by parametric and nonparametric methods.
Results: The effect of LAVE methods is prominent in analytes which reﬂect nutritional status, inﬂammation and
muscular exertion, indicating that inappropriate results are frequent in any country. The validity of the paramet-
ric method was conﬁrmed by the presence of analyte-speciﬁc distribution patterns and successful Gaussian
transformation using the modiﬁed Box-Cox formula in all countries. After successful alignment of RVs based
on the panel test results, nearly half the analytes showed variable degrees of between-country differences.
This ﬁnding, however, requires conﬁrmation after adjusting for BMI and other sources of variation. The results
are reported in the second part of this paper.
Conclusion: The collaborative study enabled us to evaluate rational methods for deriving RIs and comparing the
RVs based on real-world datasets obtained in a harmonized manner.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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The reference interval (RI) is deﬁned simply as the prediction inter-
val which includes the central 95% of reference values (RVs), or test re-
sults from well-deﬁned healthy individuals (reference individuals).
Establishment of well-controlled, reliable RIs is an important mission
for all clinical laboratories. In reality, it is very challenging, because it
is not easy to recruit a sufﬁcient number of reference individuals, to con-
trol pre-analytical variables, and to apply all statistical methods in ap-
propriate manners. The international guideline entitled “Deﬁning,
establishing, and verifying reference intervals in the clinical laboratory”
was ﬁrst published as a possible solution in 1996 by collaboration be-
tween the Clinical and Laboratory Standards Institute (CLSI) and the In-
ternational Federation of Clinical Chemistry and Laboratory Medicine
(IFCC) (the latest 2010 version is designated as CLSI/IFCC EP28-A3c (for-
merly, C28-A3) [1]. However, the descriptions are generally theoretical
in nature, and the rationales of the recommendations have not been
well evaluated by implementing actual, down-to-earth RI studies. In
fact, there have been controversies over its pragmatic aspects, such as
the rationale for secondary exclusion, the use of parametric vs. nonpara-
metric derivation, and determining how to judge the need for
partitioning RVs [2–5].
In the init terim period, for the achievement of global standardiza-
tion for major laboratory tests, the current consensus is to derive the
RIs in a reproducible manner based on sufﬁcient sample size by collab-
oration between multiple laboratories and to use the derived RIs in
common or by transference [6–8]. The Scandinavian groups conducted
amulticenter study for derivation of commonRIs based on standardized
test values and found virtually no between-country differences in the
Nordic countries [9]. However, the appropriateness of the study proto-
col and the method used for evaluating between-laboratory differences
need to be evaluated by use of newer statistical methods. In addition,
the IFCC Committee on Plasma Proteins concurrently conducted two
RI studies mainly aimed at deriving common RIs for major serum pro-
teins in East and Southeast Asian countries in 2000 and 2004; it revealed
apparent between-country differences in many of the analytes, espe-
cially those of inﬂammatory markers [10,11].
With this background and its mission of promoting proper imple-
mentation of multicenter RI studies, the Committee on Reference Inter-
vals and Decision Limits (C-RIDL) was established by the IFCC in 2005.
The primary project of the C-RIDL, as planned in early 2010, was to clar-
ify between-country differences in RIs on a global scale and to seek the
most practical and harmonizable methodologies for conducting the RI
studies. The key strategy of the global study was to make RVs compara-
ble among the countries through measurement of a common panel of
serum samples. After conducting a feasibility study to conﬁrm the valid-
ity of cross comparison of test results based on the panel test results [12]
and the elaboration of the commonprotocol [13], the globalmulticenter
study was launched at the end of 2011 on a trial basis. The moreon reference values: 1. Assessment of methods for derivation and
g/10.1016/j.cca.2016.09.016
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op a comprehensible picture of themost rational way of conducting the
RI study in an internationally harmonized way.
1) How strictly should we set-up exclusion criteria in recruitment of
candidate reference individuals? It may differ from country to
country.
2) In what situation is it necessary to exclude individuals secondarily?
What is the rational method to do so?
3) Why not just use a nonparametric method for statistical derivation
of the RI? Does the parametric method give the RI reproducibility
for each analyte?
4) How comparable are the RVs if the analytes are supposed to be glob-
ally standardized?
5) How reliable is the scheme of aligning RVs based on panel test re-
sults measured in common?
6) Are there ethnic or regional effects in the RVs?
7) Are major sources of variations (sex, age, BMI, etc.) of RVs the same
among the countries?
As of August 2015, the global study involved 17 countries from 5
continents, the majority of which sought to establish country-speciﬁc
RIs. In this intermediary report, as the ﬁrst part of the key note article
for the study, the methodologies in common use are brieﬂy described,
and the analytical results from 12 countries that had completed their
studies were evaluated collectively for addressing the ﬁrst ﬁve of the
above issues. Evaluation for the issues (6) and (7) will be presented in
a second report [14].
2. Methods
2.1. The common protocol for the study
The study protocol [13] commonly used in each country is brieﬂy de-
scribed as follows:
2.1.1. Recruitment
The target population was apparently healthy individuals 18–
65 years of age with equal gender and age distributions. Those above
65 years were also included, even with small sample sizes. The test re-
sults of that age range were not used for any data analysis except in
making proﬁles for sex- and age-related changes of reference values
for the extended age range.
All potential participants should be feeling subjectively well. Any
subject taking medications or vitamin supplements had them recorded
(name, dose and frequency) so that secondary exclusion after measure-
ment could be done as required. The following medications were re-
corded but permitted: contraceptive pills or estrogens, plus thyroxine
if the subject was maintained in a euthyroid state (TSH b upper refer-
ence limit).
Exclusion criteria were known diabetes on oral therapy or insulin
(diet alone is acceptable); a history of chronic liver or kidney disease;
blood test results that clearly point to a severe disease; a history of
being a hospital inpatient or otherwise seriously ill during the previous
4 weeks; blood donation in the previous 3 months; known carrier state
for HBV, HCV, or HIV; female participants who were pregnant, breast
feeding, orwithin one year after childbirth; any other signiﬁcant disease
or disorder which, in the opinion of the investigator, might either put
the participants at risk because of participation in the study ormight in-
ﬂuence the results of the study; or participation in another research
study involving an investigational product in the past 12 weeks.
2.1.2. Sampling, storage and measurements
Blood sampling from the volunteers was done under basal condi-
tions, including overnight fasting of N10 h, sitting for at least 20 min
prior to sampling, and avoidance of strenuous muscular exertion for
three days or working a night shift before the sampling. Sera werePlease cite this article as: K. Ichihara, et al., A global multicenter study
comparison of reference intervals, Clin Chim Acta (2016), http://dx.doi.orseparated soon after sampling and stored immediately at−80 °C. This
was because all specimens were tested collectively in batches in each
country's central laboratory regardless of the time of sampling.
2.1.3. Target analytes and measurements
The 50 target analytes for the study were as described in the com-
mon protocol [13] and were composed of standardized analytes (lipids,
electrolytes, enzymes,major serumproteins) and non-standardized but
harmonizable analytes (inﬂammatory and tumor markers, hormones
and vitamins). All were measured in the serum samples by use of auto-
mated analyzers employed in each central laboratory for routine use.
Quality control of the assays was performed by use of commercial QC
sera of routine use and the mini panel composed of 5−6 sera from
healthy individuals [5].
2.2. The serum panel and assignment of traceable values for standardization
Two serumpanelswere produced by the C-RIDL in 2011 and in 2014,
respectively composed of 80 (all Japanese) and 100 (70 Japanese; 30
from other ethnicities) sera from healthy individuals with nearly equal
gender and age (20–65 years) proportions. The scheme of the value as-
signment for theﬁrst panel for standardized analyteswas described pre-
viously [5,13]. The second panel was divided into two parts, one for
chemistry analytes including those measured by immunoturbidimetry,
and the other for analytes measured by other immunoassays. Assign-
ment of values traceable to the reference measurement procedures
(RMPs) for ﬁve chemistry analytes (TC, TG, urea, UA, Cre), and for
seven enzymes (AST, ALT, LDH, GGT, ALP, CK, AMY) was performed by
reference laboratories associated with the Committee on Traceability
of Laboratory Medicine (C-TLM) of IFCC: the University of Bonn Faculty
of Medicine (led by Dr. Anja Kessler and Prof. Lother Siekmann) and the
Hanover University School of Medicine (Prof. Gerhard Schumann).
More speciﬁcally, for the ﬁrst ﬁve analytes, six sera out of the 50
chemistry part of the panel were chosen for each analyte so that
their values covered a wide portion of the presumptive RIs: i.e., a
total of 25 sera (3–6 levels × 5 analytes) were directly value
assigned. The indirect value assignment was accomplished by col-
laborative measurement of all 50 sera in ﬁve leading laboratories
in China (Beijing Union Medical School Hospital, Beijing), South Af-
rica (PathCare Laboratories, Cape Town), Japan (Beckman-Coulter
Laboratory, Mishima, Shizuoka), and Canada (Hamilton General
Hospital, Hamilton, Ontario). Based on the linear relationship be-
tween the assigned and measured values for the 3 – 6 sera, all 50
test results were recalibrated. Finally, the average recalibrated
values for each of the 50 sera were adopted as the indirectly
assigned values.
For the 7 enzymes, three pooled sera with different enzyme activi-
ties covering the presumptive RIs were ﬁrst prepared for each enzyme.
The 3 × 7 pooled sera were then value assigned directly for use as the
calibrators. The 50 sera in the chemistry part of the panel were assigned
values of their enzyme activities indirectly by use of the three sets of cal-
ibrators for each enzyme.
The list of assigned values for the 50 chemistry samples of the panel
is shown in Suppl. Table 1, which also includes tables of assigned values
for the ﬁrst serum panel both in SI and conventional units [5].
2.3. Alignment/harmonization of reference values among the countries
The basic scheme for conducting the global study was to make test
results comparable among the countries based on the panel test results
measured in common. All pairwise method comparisons were per-
formed by use of major-axis linear regression analysis (MALRA) [12].
As a result, even if values from a laboratory were biased despite the as-
sumption of standardization, accurate comparison across the countries
was still possible by recalibration of results from all the laboratories
into those matched to assigned values of the panel in the case ofon reference values: 1. Assessment of methods for derivation and
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sults from any country were aligned to those of a speciﬁed country for
harmonized comparison of reference values.
In order to perform this recalibration or alignment procedure appro-
priately, the allowable limits of errors in converting values were formu-
lated based on the theory of allowable analytic errors [5,12]. The theory
in brief is as follows. The precision of RI limits (LL, UL), converted from
one laboratory to another, based on the major-axis regression can be
expressed in twoways. The ﬁrst is by the SD ratio (SDR) of the standard
error (SE) of LL or UL to the SD comprising RI [(UL-LL)/3.92], SDRLL
(=SELL/SDRI) or SDRUL (=SEUL/SDRI). The other is by the CV of the re-
gression slope b, CV(b). Analogous with the theory of allowable analyt-
ical bias [15], SDR ≤ 0.125 is regarded as optimal, and SDR ≤ 0.25 as
desirable. We demonstrated that there was a close linear relationship
betweenCV(b) and SDRLL or SDRUL [12], and SDR=0.125 corresponded
to CV(b) = 5.5%, and SDR = 0.25 to CV(b) = 11.0%. In this study, for
aligning test results of any given analyte by the regression, we regarded
CV(b) ≤ 5.5% as indicating the conversion error is at the “optimal” level,
and 5.5 b CV(b) ≤ 8.0% as indicating “acceptable”. No alignment proce-
dure was performed if CV(b) ≥ 8.0%.
2.4. Statistical analysis
2.4.1. Expression of between-group differences based on ANOVA
The magnitude of between-country or between-region differences
was expressed as SDR. By use of one-way ANOVA, between-country
SD (SDcnt) and net between-individual SD (SDBI) (after adjusting for
the between-country variations) were calculated and their ratio was
set as the SDR [5]. Analogous to the theory of allowable analytical bias,
the critical limit for SDR (=SDcnt/SDBI) can be set to 0.25. However,
the denominator, SDRI, tends to be narrower when it is computed by
ANOVA, especially by use of two or more-level nested ANOVAwith suc-
cessive subtraction of factor-dependent variations. This implies that the
SDR is increased in proportion to a decrease of its denominator; there-
fore, we chose 0.3 rather than 0.25 as a guide for judging the practical
implication of between-country differences. In this calculation of SDR,
reference values of analytes with obviously skewed distributions, such
as TG, ALT, GGT, and CRP (their names are marked by asterisks in Fig.
3), were logarithmically transformed before applying the ANOVA, and
then, SDs in untransformed scales were computed through a method
of reverse transformation as described previously [16].
2.4.2. Latent abnormal values exclusion (LAVE) method
Inevitably some individuals who had commonly-occurring latent
diseases or who failed to observe the basal conditions required before
samplingwere included in the studypopulation. To overcome this prob-
lem, the LAVE method was developed, which makes use of the associa-
tions between abnormal values found in different analytes which are
caused by commondisorders such as themetabolic syndrome,muscular
damage and latent inﬂammation. LAVE is an iterative optimization
method for reﬁning reference individuals by excluding subjects
possessing abnormal values in related analytes [2,4,5]. Its advantageous
features are (1) truncation of reference distributions does not occur, un-
like conventionalmethods of outlier exclusion, because it excludes indi-
viduals who have results outside RIs of analytes other than the one for
which the RI is being derived, and (2) there is no effect on analytes
whose values are rarely outside the RI in healthy individuals. The disad-
vantage is a reduction in the number of subjects included in the statis-
tics, but this reduction should be minimal, depending on how strictly
the exclusion criteria have been set and how many extreme values are
allowed in the selection process. In this study, 10 analytes (Alb, UA,
Glu, TG, AST, ALT, LDH, GGT, CK, CRP) were set as reference tests
(RTs), and one value outside the RI was allowed among them. In the
procedure, the RI (LL–UL) of RTs was extended on both ends by 5% of
the width of the RI, or (UL–LL) × 0.05. Therefore, assuming a Gaussian
distribution of RVs, the extended RI (RI’) corresponded to thePlease cite this article as: K. Ichihara, et al., A global multicenter study
comparison of reference intervals, Clin Chim Acta (2016), http://dx.doi.ormean ± 2.156 SD or the central 97% ranges of RVs [2]. The probability
(Pr) of having two or more abnormal results in “fully normal” individ-
uals is computed by use of 10 RTs with assumption of no association
of test values among the RTs.
Pr two or more values outside RI’ð Þ
¼ 1−Pr no value outside RI’ð Þ−Pr one outside RI’ð Þ
¼ 1:0− 0:97ð Þ10−10C1  0:97ð Þ9 0:03ð Þ1
Therefore, the inﬂuence of the LAVE procedure is not great in deriv-
ing the RI as a central 95% range. On the other hand, if test results of RTs
are associated with each other, and there exist individuals with latent
abnormal results among RTs, reduction in the data size remaining as
“full normal” will be greatly reduced. In this study, the performance of
the LAVE methods was evaluated by comparing the RIs determined
with or without applying it in various ways.
2.4.3. Derivation of the RI and 90% conﬁdence interval (CI) of the RI limits
The RIs were derived using both parametric and nonparametric
methods.
For the parametric method, reference values were ﬁrst transformed
to Gaussian by use of a modiﬁed Box-Cox equation [2,4]:
X ¼ x−að Þ
p−1
p:
From the mean and SD in the transformed scale (mT, SDT), the
central 95% interval was given as mT ± 1.96 SDT. Then, the lower
limit (LLT = mT − 1.96 SDT) and upper limit (ULT = mT + 1.96
SDT) were back-transformed to obtain the RI (LL ~ UL) in the original
scale as follow:
LL ¼ pLLT þ 1
 1
p þ a UL ¼ pULT þ 1
 1
p þ a
For the nonparametric method, reference values were ﬁrst sorted,
and the 2.5 and 97.5 percentile points were determined. The 90% CI
for the LL and UL were predicted by the bootstrap method with repeti-
tive resampling of 100 times both for the parametric and nonparametric
methods. For smoothing the RI, average values for LL, Me, and UL were
adopted as the ﬁnal RI.
3. Results
3.1. The source data assembled
3.1.1. Composition of healthy volunteers from 12 countries
Included in this intermediary report were the results from 12 coun-
tries: China (CHN), Japan (JPN), Philippines (PHL), India (IND), Pakistan
(PAK), Saudi Arabia (SAU), Turkey (TUR), Russia (RUS), UK (GBR),
South Africa (ZAF), USA, and Argentina (ARG). The demographic pro-
ﬁles of each country's study are summarized in Table 1. The total num-
ber of subjects was 13,396 (male 6347; female 7049).
No ethnicity related distinctions of individuals were made for any
countries except South Africa, where RVs were partitioned as Africans
and non-Africans. The following are the known ethnic composition of
the study subjects from countries other than South Africa. Japan: all Jap-
anese; China: all Han Chinese; India: all Indian; the Philippines: the vast
majority were Filipino; Pakistan: all Pakistani; Saudi Arabia: all Saudi;
UK: themajority (82%)were British; Turkey: no characterization by eth-
nicity was made; Russia: all Caucasian; USA: the majority were Cauca-
sian Americans; Argentina: the majority were Caucasian. Please note
that no within country regional differences were observed in China
[17], Japan [18], Saudi Arabia [19], and Turkey [20].
Although the number of individuals above 65 years of age varied
greatly, the distributions of ages under 65 are well balanced ason reference values: 1. Assessment of methods for derivation and
g/10.1016/j.cca.2016.09.016
Table 1
Demographic proﬁles of each country's study.
Male Female
N by age BMI Drk (%) Smk (%) drug Tx% N by age BMI Drk (%) Smk (%) drug Tx%
Area Central lab N all 18−65 66~ dHT dDL
dHU
HR Thy all 18−65 66~ dHT dDL
dHU
OC
China Nationwide Beijing Union Hosp 2621 1249 1163 86 23.6 ± 3.0 23.5 29.1 3.2 0.2 0.1 1372 1279 93 22.3 ± 2.9 2.0 0.8 3.4 0.7 0.0
Chongqing 527 260 240 20 23.1 ± 2.5 39.6 42.3 0.4 0.0 0.0 267 251 16 21.9 ± 2.4 2.2 2.6 0.4 0.0 0.0
Japan Ube, Osaka, Hiroshima, BC Mishima Laboratory 655 295 264 31 22.9 ± 2.6 53.6 19.3 8.8 2.7 0.3 360 324 36 21.0 ± 2.5 40.0 10.0 5.0 5.3 1.4
India Mumbai P.D.Hinduja National
Hosp
512 257 244 13 24.6 ± 3.5 24.5 7.8 4.3 0.0 1.2 255 247 8 24.5 ± 4.4 2.7 0.4 3.1 0.4 0.0
Philippines Iloilo city BC Mishima, Japan 757 246 245 1 23.0 ± 3.8 20.3 24.0 8.1 0.0 0.0 511 508 3 23.2 ± 4.2 1.6 6.1 7.0 0.2 5.9
Pakistan Panjab Armed Force Instit of
Pathology
561 311 303 8 24.1 ± 3.6 3.2 2.9 0.0 0.0 0.0 250 246 4 25.0 ± 4.7 6.8 0.8 0.0 0.0 0.0
Saudi
Arabia
Jeddah, Hassa Riyadh, King Khalid National
Guard Hosp, Jeddah
822 396 389 7 28.5 ± 5.6 0.0 16.9 1.0 4.5 0.0 426 418 8 28.0 ± 6.1 0.0 1.9 1.4 2.3 0.2
Turkey Nationwide Uludag University 3172 1589 1450 139 26.6 ± 3.6 10.2 24.6 3.7 0.9 0.3 1583 1440 143 25.7 ± 4.9 8 21 5.5 0.7 0.0
Russia Moscow, Yekaterinburg,
St Petersburg,
Helix Laboratories 796 370 340 30 26.6 ± 4.5 43.0 31.1 2.4 0.0 0.0 426 381 45 25.3 ± 5.6 39.2 16.0 3.1 0.7 3.1
UK Leeds Leeds Inﬁrmary 301 114 113 1 26.0 ± 3.3 78.1 8.8 2.6 0.0 0.9 187 179 8 25.5 ± 4.3 69.0 10.2 3.7 0.0 0.0
South Africa
(African)
Cape Town, Johannesburg PathCare Laboratories 651 340 333 7 26.0 ± 5.8 5.6 1.8 0.0 0.0 0.0 311 304 7 27.5 ± 5.9 3.5 0.3 0.0 0.0 0.3
South Africa
(Non African)
594 199 194 5 25.9 ± 3.7 56.3 13.6 1.0 2.0 0.0 395 379 16 24.6 ± 4.3 48.9 12.7 1.8 0.8 12.2
US Rochester, MN Mayo Clinic 244 92 84 8 27.2 ± 5.1 65.2 5.4 5.4 8.7 4.3 152 135 17 26.2 ± 5.2 66.4 3.3 7.9 7.2 15.1
Salt Lake, UT ARUP Lab 250 125 119 6 28.7 ± 5.8 36.8 4.0 7.2 4.8 1.6 125 120 5 27.0 ± 6.9 50.4 4.8 3.2 2.4 9.6
Davis, CA BC Mishima, JPN 395 191 169 22 25.6 ± 3.6 79.6 5.2 5.2 1.6 1.6 204 172 32 24.8 ± 5.1 69.6 2.0 7.8 1.5 11.8
Argentina Buenos Aires Univ of Buenos Aires 528 313 313 0 27.3 ± 4.0 47.0 22.7 3.8 1.0 0.0 215 213 2 25.4 ± 4.8 38.1 27.9 3.7 0.0 0.0
Total 13386 6347 5963 384 23.9 20.9 3.32 1.06 0.32 7039 6596 443 15.3 9.08 3.8 1.1 2.3
BMI: body mass index (mean ± SD); Drk: alcohol intake; Smk: smoking; drug Tx%: % under drug therapy; dHT: drug for hypertension; dDL: drug for dyslipidemia; dHU: drug for hyperuricemia; HR Thy: thyroid hormone replacement; OC: oral
contraceptive or female hormones
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6 K. Ichihara et al. / Clinica Chimica Acta xxx (2016) xxx–xxxshown in Suppl. Figs. 1-1 and 1-2. Distributions of BMI differed
greatly among the countries. The inﬂuence of these factors on the
analysis of RVs will be described in part 2 of this report [14]. The pro-
portions of those who smoked cigarettes were quite comparable
among the countries. In contrast, the proportions of individuals
who drank occasionally or regularly differed greatly between coun-
tries, partly for religious reasons.
For medications, we focused on drugs for hypertension (dHT) and
drugs for dyslipidemia and hyperuricemia (dDL and dHU), all of which
are known to affect test results for some analytes. Although the propor-
tions of individuals taking either or both categories of drugs were low,
those taking dHT were excluded from the analysis of UA, urea, Cre,
and K, those taking dDL from the analysis of lipids, and those taking
dHU from the analysis of UA. Oral contraceptives (OC) are reported to
be associated with changes in serum levels of some chemistry analytes
[21]. From a preliminary analysis, we found TGwere higher and Alb and
ALPwere lower in users of OCs with their between users and non-users
SDR ranging from 0.3 to 0.65. Therefore, in the analysis of the three
analytes, we excluded individuals on OC (or receiving female hormone
replacement therapy) in countries where the proportions of OC users
were N5.0% (US 12.4%, Non-African in South Africa 12.9%, PHL 5.9%) of
females, while those in other countries with the proportion between
0–3.1% were neglected (Table 1).
3.1.2. Analytes and measurements
Analytes measured in each country are listed in Suppl. Table 1.
Serum proteins (CRP, IgG, IgA, IgM, C3, C4, TTR, and Tf) were measured
by immunoturbidimetry and grouped with the general chemistry
analytes. Most of the analytes except these speciﬁc serum proteins
were measured in all countries; the analytes measured by so-called la-
beled immunoassays were less frequently measured because of the
cost of reagents.
3.2. Correlations of panel test results among countries
The serumpanel of theﬁrst lot (Panel-I) was assayed by all countries
except Pakistan and the Philippines, which used the panel of the second
lot (Panel-II). South Africa measured both panels on two occasions.
The relationships between Panel I and II were evaluated in the
Beckman Coulter Laboratory (Y) in Japan by parallel measurements of
both panels. Then, the relationships between the new and past mea-
surements of Panel-I (Y vs. Y′) were evaluated. Test results of almost
all analytes were nearly identical (Y ≈ Y′), with only a few analytesFig. 1. Between-laboratory value conversion scheme based on test results of the serum panels
laboratory to another by use of major-axis linear regression analysis (MALRA). Since there w
procedure for converting RVs from Lab-X (which measured Panel II in 2015) to those of Lab-Z
which measured both Panel I and II simultaneously in 2015 and also measured Panel I once in
by use of MALRA equation (right graph). The value Y based on Panel II was identical with the
the Y measured in 2015 could be converted to the Y of 2012 (Y′) by use of the MALRA for the
was further converted to the value of Lab-Z (Z) by use of the relationship between Lab-Y and
achieved by use of the formula shown in the bottom.
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comparison of reference intervals, Clin Chim Acta (2016), http://dx.doi.orshowing bias that required recalibration by use of the linear equation
Y′=a+ bY. Using these linear relationships, it was possible to convert
test result X from Lab-X (Pakistan, South Africa) whichmeasured Panel
II to test result Z of Lab-Zwhichmeasured Panel I. As illustrated in Fig. 1,
this cross-conversion becomes possible by ﬁrst converting X to value Y
of Lab-Y, whichmeasured both Panel I and Panel II simultaneously. This
conversion of X to Y is done by use of the regression equation for Panel-
II test results: Y= a+bX. Then, from the relationship between the new
and past values (Y and Y′) for Panel I in Lab-Y: Y′= a′+ b′Y, value X is
further converted to value Y′: Y′=a′+b′(a+bX). Finally, from the lin-
ear relationship between Y′ and Z for Panel I: Z = a″ + b″Y′, X was fur-
ther converted to Z by use of the formula: Z = a″+b″{a′+b′(a + bX)}.
By use of this conversion scheme in comparing test results among
the countries, all the test results of countries which measured Panel II
were aligned ﬁrst to the values of Japan at the time of measuring
Panel I in 2012. Then, further conversions were done if necessary de-
pending on to which country's values the alignment was to be made.
Since the above procedure results in additive errors with successive
conversions, we applied CV(b) ≤ 5.5, not 8.0%, as the allowable limit of
conversion for the analysis of data from Pakistan, the Philippines, and
South Africa.
Actual test results of each participating laboratory, and assigned
values, if any, for the ﬁrst and second lots of the serum panel are
shown in Suppl. Fig. 2 by use of a correlation matrix graph.3.3. Comparison of reference values among the countries before and after
alignment
In order to compare reference values among the countries, reference
values were all aligned to the assigned values for the analytes listed in
Supp. Table 1 (TP, Cre, UA, urea, TBil, TC, TG, HDL-C, LDL-C, Ca, IP, AST,
ALT, GGT, CK, GGT, CRP, IgG, IgA, IgM, C3, C4, Tf, and TTR); they were
otherwise aligned to the values measured in Japan based on pairwise
linear regression analysis of the panel test results between assigned/
Japanese values and each country's values. Typical results are shown
for UA and Cre in Fig. 2, with full results posted as Suppl. Figs. 1-1 and
1-2, for males and females, respectively. SDRs for between-country dif-
ferences (SDRcnt) before and after alignment are shown at the top of
each graph. The full list of SDRcnt computed separately for each sex is
shown for 42 analytes in Fig. 3. Not included in the list are those analytes
whichwere measured by b6 countries (GH and ﬁve sex hormones: tes-
tosterone, estradiol, progesterone, LH, and FSH). For two analytes (Na. RVs of serum panel measured in common by two laboratories were converted from one
ere two different serum panels (Panel I and Panel II), it was necessary to make a nested
(which measured Panel I in 2012). It was achieved by use of panel test results of Lab-Y,
2012. The RV of Lab-X (X) was ﬁrst converted to that of Lab-Y (Y: measured by Panel II)
value Y based on Panel I because both panels were measured simultaneously. Therefore,
relationship between Panel I values of 2015 and 2012 in Lab-Y (middle graph). Then, Y′
Lab-Z for the Panel I test results (left graph). This serial value conversion from X to Z was
on reference values: 1. Assessment of methods for derivation and
g/10.1016/j.cca.2016.09.016
SDR= 0.48 SDR= 0.33
align
SDR= 0.38 SDR= 0.27
align
Fig. 2. Comparison of RVs across the countries before and after alignments. The distribution of RVs formaleswere compared before and after alignment based on the panel test results. The
box and center line in each scattergram represents themid 50% range andmedian of RVs, respectively. The data size are shown to the right bottom of the country name. Af and NAf for ZAF
represent African and Non-African population. SDR for between-country differences is shown on the right upper corner. The graphs are shown for two typical analytes (UA and Cre). Full
ﬁgures are available in Suppl Figs. 1-1 and 1-2.
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Fig. 3. SDR for between-country differences before and after alignment (41 analytes). For each gender, between-country differences in RVs were computed analyte by analyte as SD ratio
(SDR: between-country SD divided by net between-individual SD) before and after aligning RVs based on the panel tested results. Tabulated are 41 analytes forwhich RVs after alignment
were available from N6 countries: i.e., not shown are analytes which were measured by b6 countries or showed a large ﬂuctuation around regression line with frequent failure in the
alignment due to CV(b) N 8%. RVs were aligned to assigned values if available, otherwise, aligned to those of Japanese results. The magnitude of SDRs was depicted by the length of the
bars. As a guide, SDR = 0.3 is indicated by the vertical solid lines. Names of the analytes with SDR ≥ 0.5 are indicated by background color of orange, those with 0.5 N SDR ≥ 0.35 by
yellow, while those with 0.25 ≥ SDR are indicated by gray. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
8 K. Ichihara et al. / Clinica Chimica Acta xxx (2016) xxx–xxxand Cl), it was not possible to align values across the countries because
of the large CV(b).
Using SDRcnt ≥ 0.3 as a guide, prominent reduction in SDRcnt after
alignment was observed for urea, LDH, Mg, cortisol, and PTH. Apparent
between-county differences even after alignment were observed in
many analytes in males (M) or in females (F): Those with SDRcnt N 0.5
were Alb, Mg, TBil (F), HDL-C (F), ALT(F), CRP(F), IgG, C3(F), VitB12,
and Folate (F). However, the between-country differences observed
were crude ones not adjusted for any possible inﬂuences on test results.Please cite this article as: K. Ichihara, et al., A global multicenter study
comparison of reference intervals, Clin Chim Acta (2016), http://dx.doi.orThe most important factor which may confound the between-country
differences is BMI, which differed widely from one country to another.
The issues of adjusted comparison andmultivariate evaluation of sources
of variation (SV) are presented in the second part of this report [14].
3.4. Assessment of need for secondary exclusions
In this global study, we derived RIs in variousways in order to deter-
mine an optimal method for each analyte. Therefore, in this report,on reference values: 1. Assessment of methods for derivation and
g/10.1016/j.cca.2016.09.016
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ing differences of RIs between parametric and nonparametric methods,
and with or without application of LAVE methods.
Threemethods of deriving the RIswere compared: (1) nonparamet-
ric method without LAVE [NP-LAVE(−): CLSI method], (2) parametric
method without LAVE [P-LAVE(−)] and (3) parametric method with
LAVE allowing one abnormal result (value outside the slightly extended
RI) in the reference analytes [P-LAVE(+)]. Since the target disorders or
conditions which have high prevalence among apparently healthy indi-
viduals were those related to nutritional status ormuscular damage, we
chose the 10 analytes listed in the Methods section as the standard ref-
erence analytes to detect individuals with multiple abnormal values.
As typical examples, in Fig. 4, nine clinical chemistry analytes were
chosen for evaluation: three for LAVE insensitive analytes (urea, Cre,
K) and six LAVE sensitive ones (AST, ALT, LDH, GGT, TG, and CK). Data
were limited to those of males because of their higher prevalence of
the metabolic syndrome. The minimum number of subjects included
in a data set was 300males. This criterion led to inclusion of the follow-
ing 7 countries: CHN, SAU, TUR, RUS, ZAF, USA, and ARG.
As expected, with regard to urea, Cre, and K, there were no changes
in RI regardless of LAVEmethod, while the nonparametric method gen-
erally gave slightly wider RIs (higher ULs). For TG, AST, ALT, LDH, GGT
and CK, there was a consistent tendency for reduction of the UL of RIs
regardless of the country. ULs of RIs by the nonparametric method al-
ways were higher than those of the parametric method.
With application of the LAVE method, the reduction in data size for
calculation of the RI was between 15 and 22%, pointing to worldwide
high prevalence of latent abnormal values attributable to nutritional
disorders or failure in complying with the pre-sampling requirements
(muscular exertion, insufﬁcient resting/fasting). Please note that the
slightly smaller data size analyzed by the parametric method compared
to the nonparametric method despite non-use of the LAVE method was
due to the exclusion of values outsidemean±2.81 SD once after Gauss-
ian transformation in applying the parametric method. This procedure
of removing inﬂuential data points in the periphery is required for an
improved result in the parameter ﬁtting. This fact partly explains why
the nonparametric method gave higher ULs than the parametric meth-
od for almost all the analytes examined.
3.5. Consistency of the reference distributions and appropriateness of
Gaussian transformations
RIs for 24 chemistry analytes were derived by the parametric meth-
od separately for males and females using the datasets from 10 coun-
tries (the UK was not included because of insufﬁcient data size). The
modiﬁed Box-Cox power transformation formula was used to make
each reference distribution Gaussian (normal). The maximum likeli-
hood method was used to predict power (p), and then the origin of
transformation ‘a’ was optimized to the predictive p, iteratively. The
value p represents the distribution pattern; i.e., p b 1.0 implies thedistri-
bution has a longer tail in its higher side; p = 1.0, Gaussian (normal)
pattern or symmetrical; p N 1.0, the distribution has a longer tail in its
lower side; p≈ 0.0, log-normal.
In the left panel of Fig. 5, the distributions of the ‘p’ consisting of 20
points (10 countries × 2 sexes) were depicted for each analyte as box
and whisker plots with their spans representing the central 50% and
90% ranges, respectively; 90% was chosen rather than 95% because of
the small sample size. It is notable that almost all of the p values areFig. 4. Comparison of RIs and their 90%CI derived in three ways. RIs were derived in threeways
depicted by the horizontal bar with shades on both ends corresponding to the 90%CI derived
reference for exclusion: Alb, UA, Glu, TG, AST, ALT, LDH, GGT, CK, and CRP. They are reliable m
latent disorders commonly seen in apparent healthy individuals. Data sizes used for computat
Nine analytes were chosen for contrasting the effect of LAVE: top-three as LAVE-insensitive,
with data size of ≥300, the number of countries fulﬁlling the condition were 7: China (CHN
including non-African, USA, and Argentina (ARG).
Please cite this article as: K. Ichihara, et al., A global multicenter study
comparison of reference intervals, Clin Chim Acta (2016), http://dx.doi.orbelow 1.0, implying that the reference distributions have a tendency
of more or less larger tail toward the higher side of values. It is also of
note that each analyte has its own distribution pattern regardless of
the country. We found that the distribution pattern expressed as ‘p’
does not differ between the two sexes. From the ﬁgure, we can roughly
categorize the analytes from the p value as follows: highly skewed
(p b 0.25: very close to the logarithmic normal distribution), CRP, GGT,
CK, ALT, and TG;moderately skewed (0.25 ≤ p b 0.4: cube-root normal):
TBil, AST, and AMY; slightly skewed (0.4 ≤ p b 0.7: square-root normal):
ALP, Urea, LDH, Fe, HDL-C, TC, LDL-C, UA, Cre, and K; almost normal
( 0.7 ≤ p ): Cl, Na, Alb, IP, Ca, and TP.
The success of the Box-Cox formula in transforming the reference
distribution into the Gaussian pattern was evaluated by computing
the skewness (Sk) [22], which reﬂects the degree of symmetry of the
distribution. In the right panel of Fig. 5, the distributions of Sk computed
after Gaussian transformation are depicted for each analyte using the
same drawing scheme as the left panel. As shown on the top right,
the Sk values for Gaussian (p= 1.0) and log-Gaussian (p= 0.0) dis-
tributions are theoretically 0.0 and 3.8, respectively, while the distribu-
tions with |Sk| b 0.2 are almost indistinguishable from the Gaussian
distribution by inspection. It is obvious from the ﬁgure that the modi-
ﬁed Box-Cox formula was very successful in transforming the reference
distributions into Gaussian form in the vast majority of the cases. The
conformity of power-transformed values to the Gaussian distribution
was also evaluated by performing three statistical tests (test of skew-
ness, χ2 test of goodness-of-ﬁt, and Kolmogorov–Smirnov test) and by
visual inspection of probability plots (cumulative frequency on Y-axis
and a power-transformed value on X-axis). Used for those evaluations
were two examples of male datasets from Saudi Arabia and Japan that
remained after the application of the LAVE method. The ﬁnal data
sizes were approximately 320 and 215, respectively.
Although the statistical testing of the datasets with those data sizes
is generally very sensitive to a slight deviation from the Gaussian
form, power-transformed values of any analytes were almost invariably
judged as not signiﬁcant (Suppl. Table 3). The probability plot (Suppl.
Fig. 3) also showed linearity for its main segment (cumulative frequen-
cies of 10 – 90%), except for the CRP dataset from Japan which required
non-parametric derivation of its RI.
These ﬁndings support the reproducibility and accuracy of the para-
metric method in estimating the central 95% range of the reference
distribution.4. Discussion
The choice of appropriate reference individuals for the study of RIs
(RI study) is a challenging problem. It is expected that reference individ-
uals are healthy without any disease or condition which affects test re-
sults of the analyte for which the RI is being determined. It is usually
essential to determine RIs for as many analytes as practical in the
same samples for the sake of efﬁciency. However, it is difﬁcult to ﬁnd in-
dividualswho fulﬁll “normal” requirements for all the analytes. Further-
more, it is not easy to identify individuals who have latent disorders
beforehand without the actual tests being evaluated. If the prevalence
of a disorder is low, this does not pose a problem in determining the
RIs. In contrast, if the prevalence is relatively high, it is crucial either to
apply very strict exclusion criteria in recruitment or to apply secondary
exclusion after testing.by nonparametric (NP) or parametric (P)methodwith/without LAVEmethod. Each RI was
by the bootstrap method. LAVE method was applied by use of the following test items as
arkers of nutritional derangement, muscular exertion or inﬂammation which constitute
ion of the RIs after the selection process are shown next to the Y-axis for each subgroup.
and other six as LAVE-sensitive analytes. Since the RIs were derived for male subgroup
), Saudi Arabia (SAU), Turkey (TUR), Russian (RUS), African of South Africa (ZAF) not
on reference values: 1. Assessment of methods for derivation and
g/10.1016/j.cca.2016.09.016
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Fig. 5. The power (p) required for Gaussian transformation of reference values and the skewness after the transformation. In the process of deriving the RIs by use of parametric method,
the distribution pattern of RVswerepredicted as thepower (p) by regression to themodiﬁedBox-Cox formula forGaussian transformation. The success of the transformationwas assessed
by the skewness (Sk) of the distribution: i.e., |Sk| ≤ 0.2 indistinguishable fromGaussian pattern and |Sk| ≤ 0.3 very close toGaussian pattern. Distribution of 20 p and Sk values,whichwere
obtained from 10 countries in the derivation of RIs separately for males and females, were compared for 24 chemistry analytes. The spans of the box and whisker drawn for each analyte
represent central 50% and 90% range of the values.
11K. Ichihara et al. / Clinica Chimica Acta xxx (2016) xxx–xxxIn the global study, the objective was to have a harmonizable, prag-
matic protocol for conducting the RI study which could be applicable to
all participating countries. Therefore, we had to apply a lenient policy
for recruitment without setting any limitation to BMI, habits of alcohol
drink or smoking, and even use of common medications, as long as
the individuals were feeling healthy and did not have any chronic
renal or hepatic disorder or a past history of signiﬁcant diseases.
This policy inevitably required us to apply secondary exclusions
criteria customized to each analyte and to some countries. The exclusion
was done on an analyte by analyte basis for those on medications. For
example, for subjects who were on medication or supplements which
may affect lipids, Fe, Ca, vitaminD, B12, and folatewere excluded. A sim-
ilar approach was taken for subjects on antihypertensive drugs which
may affect urea, UA, Cre, and K values. However, the percentage of indi-
viduals who were on these drugs was low (b10% for individuals over
50 years of age), indicating reasonable self-restraint on the part of
volunteers.
Aside frommedications, it ismost important to remove the inﬂuence
of latent diseases or commonly-occurring conditions as much as possi-
ble. In the CLSI/IFCC document EP28-A3c, this problem is treated as a
univariate issue and thus outlier exclusion methods, such as the Dixon
method [23] or Tukey method [24], are listed, although EP28-A3c dis-
courages them, emphasizing the need for proper selection of individuals
in the ﬁrst place. In general, the outlier exclusion is applicable only to
data of a very small sample size. For a larger sample size, there is no
such concept as outliers but a cluster of abnormal results, and thus, re-
peated application of outlier exclusion leads to truncation of the refer-
ence distribution without prior transformation of RVs. In the global
study the LAVEmethodwas adopted as the solution,which corresponds
to amultivariate approach depending on co-occurrence of abnormal re-
sults among mutually related analytes. However, appropriate selection
of “reference analytes” which are used to judge the latent disorders is
crucial. Since the most common disorders or conditions which affectPlease cite this article as: K. Ichihara, et al., A global multicenter study
comparison of reference intervals, Clin Chim Acta (2016), http://dx.doi.orthe basic laboratory tests are the metabolic syndrome, strenuous exer-
cise-related muscular damage, and sampling without fasting or enough
resting, for the clinical chemistry analytes, the following 10 tests were
chosen as the reference: Alb, UA, Glu, TG, AST, ALT, GGT, LDH, CK, and
CRP. Most of them are known to be affected by nutritional status and
by chronic inﬂammation, and CK, LDH and AST reﬂect muscular dam-
age. There have been almost consistent reports indicating that TG,
AST, ALT, GGT, LDH, CK, and CRP are LAVE-sensitive analytes [16–20,
25,26]. We conﬁrmed this ﬁnding by looking at the RIs with or without
LAVE among the countries as shown in Fig. 4. The consistent ﬁnding of a
fairly large reduction in data size in any country indicates that a sizable
number of inappropriate results are invariably present and should be
processed multivariately by use of LAVE method, not univariately by
use of outlier detection methods.
On the other hand, for urea, Cre, and K, no difference of the RIs were
observed regardless of the use of the LAVE method in any country. For
those analytes the LAVEmethod is of no use and leads only to reduction
of the sample size and expansion of the 90% CI of the RI.
The possibility of too great a reduction in data size by applying the
LAVE method can be a concern. The relative decrease in data size can
be reduced if we apply stricter exclusion criteria at the time of recruit-
ment. In reality, however, that policy makes it difﬁcult to recruit a sufﬁ-
cient number of volunteers. On the other hand, the LAVEmethod can be
applied in a looser way either by allowing up to two abnormal results
among the reference analytes, or by a 2 to 5% expansion of the RI limits
(LL, UL) of each reference analyte in judging abnormality. In fact, the
LAVEmethod is a pragmatic solution to optimize the RI in face of an un-
certain number of inappropriate results. Therefore, procedures for ap-
plying LAVE have to be determined on a trial and error basis and are
thus dependent on the policy of the organizer of the study. Despite
this empirical nature of the LAVEmethod, with the consistency of its ef-
fect across the countries, the LAVE based RIs are currently accepted by
all the collaborating investigators.on reference values: 1. Assessment of methods for derivation and
g/10.1016/j.cca.2016.09.016
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the CLSI/IFCC guideline was the failure of Gaussian transformation by
the Box-Cox transformation [1,27]. Therefore, it has been thought that
the pattern of reference distribution is uncertain and cannot be
expressed by the known mathematical formula on which the paramet-
ric method relied. As expected, the nonparametric method was recom-
mended instead. However, it has been shown that the parametric
method works appropriately when the modiﬁed Box-Cox power trans-
formation formula is used, which includes the origin of transformation
‘a’ as an additional parameter to be ﬁtted [2,4,5]. In this study, by com-
piling the intermediary data obtained in the process of computing RIs
for each country, it now became clear that the reference distribution
can be successfully transformed into theGaussianpattern almost invari-
ably, judged from the virtual lack of skewness after the transformation
(Fig. 5, right panel; Suppl. Table 3; Suppl. Fig. 3). As for the controversial
view of uncertainty about the distribution pattern of RVs, we have dem-
onstrated that, viewed across countries, there is consistent pattern of
distributions speciﬁc to each analyte (Fig. 5, left panel). This implies
that the power required for Gaussian transformation is not determined
by chance, but it is predetermined for a given analyte regardless of the
countries. In fact, the p values (power) of the reference distributions
for both males and female were very similar.
These ﬁndings imply that the parametric method based on themod-
iﬁed Box-Cox formula is themethod of choice for deriving RIs in almost
all situations. A known exception is a situation where the reference dis-
tribution is truncated on its lower side due to a limited level of assay
quantitation. We encountered this problem in the derivation of the RIs
for CRP (measured by routine and not high sensitivity methods), PSA
in females, rheumatoid factor, and anti-thyroglobulin antibody. It was
necessary to use the nonparametric method or a probability plot meth-
od for estimating the upper 2.5 or 5% limit. Another situation where the
parametric method is not appropriate is when there are only an insufﬁ-
cient number of RVs for computing the RI. The method is sensitive to
outlying points with data size below 150. However, this problem is eas-
ily overcome by applying the bootstrap resamplingmethod to the same
dataset and adopting the average LL and UL as the ﬁnal limits of the RI.
We used this smoothing technique both for the parametric and non-
parametric methods.
So far we have discussed the C-RIDL task of establishing optimal
methodologies for derivation of RIs, which was made possible through
the comparison of analytical results gathered from the RI studies around
the world. Another important task of C-RIDL was to put together RVs
from around the world, overcoming the problems of insufﬁcient stan-
dardization or non-harmonized status of assay methods. Our objective
was to compare the RVs through harmonization and to investigate the
regionality and ethnicity of RVs on a global scale. If successful, the infor-
mation we collected is expected to contribute to globalized medical
practice.
In the history of laboratorymedicine, there have been no attempts to
overcome the difﬁculties in establishing collaborative teams needed to
recruit a large number of reference individuals in a harmonized way.
Fortunately, toward the end of 2011, several laboratories from 17 coun-
tries willingly joined the study in response to the C-RIDL's call for
participation.
C-RIDL proposed that to achieve the goal, the key strategy was to
produce a serumpanel composed ofmany individual commutable spec-
imens and to ask for its measurement by all collaborating laboratories
for cross-comparison of the results. Conventionally, a panel of sera has
been used mainly as a reference set of specimens for the validation of
an assay under evaluation. It was necessary to conﬁrm the feasibility
of using it for aligning test results among the countries. In early 2011,
60 sets of the serum panel (the ﬁrst lot), composed of 80 specimens
from healthy individuals, were produced, and the feasibility study was
carried out in spring of 2011 through collaboration among 4 laborato-
ries from the US, Turkey and Japan [12]. The results clearly revealed
the usefulness of the panel in aligning test results by pair-wisePlease cite this article as: K. Ichihara, et al., A global multicenter study
comparison of reference intervals, Clin Chim Acta (2016), http://dx.doi.orcomparison of test results among collaborating laboratories, and the
concept of allowable limit of error using CV(b) was also elaborated.
From this study, the practicality of the scheme of using the panel
for cross-comparison and alignment of RVs has now become obvious.
It is of note that some bias existed even for standardized analytes,
and it was necessary to make adjustment for proper comparison of
the results. Furthermore, the assignment of serum panel values
traceable to the RMPs proved to be very useful for recalibration of
the RVs and RIs. As an important outcome of the scheme, we showed
an absence of between-country differences (SDRcnt b 0.3) regardless
of sex in RVs for TG, Fe, LDH, ALP, IgM, Tf, AFP, CEA, CA125, PSA, cor-
tisol, PRL, and TSH. In contrast, prominent differences in both sexes
(SDRcnt N 0.4) were revealed in RVs for TP, TBil, HDL-C, Mg, CRP,
IgG, C3, and Vit-B12. It is important to note, however, that these ﬁnd-
ings need to be conﬁrmed by multivariate analysis to adjust for pos-
sible confounding effects of age, BMI and other sources of variation of
RVs. The results of the detailed analyses are to be described in the
second part of this report [14].
C-RIDL is now considering another utility of the panel: to provide a
service of transferring the RIs determined country by country to any
party (clinical laboratories or IVD manufacturers) that is interested in
conﬁrming, comparing or introducing the RIs without actually
conducting an RI study. If some bias is found from the panel test results,
the RI can be recalibrated easily based on the regression analysis. If the
purpose is just to verify the RIs before transference or just to conﬁrm the
standardized status of the assay, it is not necessary to measure all of the
sera in the panel. Only 5 to 10 sera are enough if their concentrations are
widely apart. Exceptions are some analytesmeasured by immunoassays
showing a high degree of molecular heterogeneity or assay imprecision
[12]. It is notable that certiﬁed reference materials (CRMs) currently
available are composed of just one to three specimens. Recalibration
of any assay based on a few data points is not accurate, no matter how
precisely CRMs were measured. In contrast, the specimens in the
serum panel are value assigned for many of the standardized analytes.
Therefore, only a small fraction of the panel is sufﬁcient for use either
to conﬁrm the state of standardization or to recalibrate the RIsmore ac-
curately than CRMs. However, to make use of the panel for these pur-
poses, it is necessary to produce a large number of aliquots of a
smaller sub-set of a panel tomake themwidely available.With this per-
spective in mind, the second panel, fully value-assigned for the 12
analytes, was produced in 2014. It is now possible to produce multiple
“secondary” serum panels inheriting the values from the second panel,
each of which is composed of a smaller number of sera with traceable
values. C-RIDL has now set this as one of the most important activities
for the coming years.
5. Conclusion
There were two main objectives in the C-RIDL's global project. One
was to establish optimal methodologies for derivation of RIs through
analysis of real-world datasets gathered from studies around the
world. The other was to put together RVs on a global scale for compar-
ison after harmonization and for exploration of the regionality and eth-
nicity of these RVs among all countries. Both objectives were achieved
as planned, and the controversial issues posted at the beginning of
this article were answered as below:
1) The strict criteria for recruitment tailored to each countrymaynot be
necessary if investigators in each country make efforts by their own
standards of “healthiness”, and the measures below are applied.
2) In the situation where test results from healthy volunteers are ex-
pected to contain a sizable number of abnormal results due to the
presence of common diseases or conditions inﬂuencing test results
of the analyte concerned, it is deﬁnitely necessary to apply some
measures for secondary exclusion regardless of the country. The
more rational one is not outlier exclusion methods (univariateon reference values: 1. Assessment of methods for derivation and
g/10.1016/j.cca.2016.09.016
13K. Ichihara et al. / Clinica Chimica Acta xxx (2016) xxx–xxxapproach), but rather the LAVEmethod (multivariate approach) de-
spite the reduction in the data size.
3) The parametric method is applicable for derivation of the RIs almost
invariably. Its validity was suggested from the consistent pattern of
reference distributions speciﬁc for each analyte. On the other hand,
the nonparametric method is applicable but not recommended
when abnormal results are expected in test results from healthy in-
dividuals because there is no way to fully exclude them non-
parametrically.
4) Some bias in the RVs existed even for the standardized analytes.
Therefore, it is essential to make cross-comparison of them by use
of multiple commutable specimens (serum panel) in conducting
the multicenter study for derivation of the RIs.
5) Unbiased comparison of the RVs for most analytes is possible by use
of the serumpanel regardless of the standardized status of the assay.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2016.09.016.
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